Virginia Mara de Deus Wagatsuma

Virginia Mara de Deus Wagatsuma

Auto-generated profile, based on publicly available information

Virginia Mara de Deus Wagatsuma

Laboratory of Experimental Hematology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
AYAparecida Yulie Yamamoto
Aparecida Yulie Yamamoto
MMMARISA MUSSI-Pinhata
MARISA MUSSI-Pinhata
SBSuresh B. Boppana
Suresh B. Boppana
ZNZdenek Novak
Zdenek Novak
VWVirginia M. Wagatsuma
Virginia M. Wagatsuma
WBWilliam J. Britt
William J. Britt

27 June 2007 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
AYAparecida Yulie Yamamoto
Aparecida Yulie Yamamoto
MMMARISA MUSSI-Pinhata
MARISA MUSSI-Pinhata
VWVirginia Mara de Deus Wagatsuma
Virginia Mara de Deus Wagatsuma
LMLauro Juliano Marin
Lauro Juliano Marin
GDGeraldo Duarte
Geraldo Duarte
LFLuis Tadeu Moraes Figueiredo
Luis Tadeu Moraes Figueiredo

15 May 2012 in Tissue Antigens
Verified
Journal Article
Closed access
PDF file
MRM. C. Rocha‐Júnior
M. C. Rocha‐Júnior
RHR. Haddad
R. Haddad
DAD. C. Cilião Alves
D. C. Cilião Alves
VWV. M. de Deus Wagatsuma
V. M. de Deus Wagatsuma
CMCelso Teixeira Mendes-Junior
Celso Teixeira Mendes-Junior
SKSimone Kashima
Simone Kashima

1 March 2015 in Viral Immunology
Verified
Journal Article
Open access
SSSvetoslav Nanev Slavov
Svetoslav Nanev Slavov
SKSimone Kashima
Simone Kashima
VWVirginia M.D. Wagatsuma
Virginia M.D. Wagatsuma
APAna Cristina Silva Pinto
Ana Cristina Silva Pinto
Edson Zangiacomi MartinezEdson Zangiacomi Martinez
Edson Zangiacomi Martinez
DCDimas T. Covas
Dimas T. Covas
The role of the human cytomegalovirus (HCMV) infection in individuals with hemoglobinopathies is unclear. Our objective was to examine the molecular and genotypic characteristics of HCMV in patients with sickle cell disease, beta-thalassemia major, and volunteer blood donors by viral load quantitation, glycoprotein B (gB) genotyping, and phylogenetic analysis. The patients with sickle cell disease demonstrated the highest HCMV DNA prevalence (13.8%), followed by the patients with beta-thalassemia major (7.6%), and the blood donors (3%). The infection was characterized by a low mean viral load (3.8×10(3) copies/mL), but infections with higher copy numbers were also observed. Genotype gB2 was detected in the majority of cases (90.9%), followed by genotype gB1 (9.1%). No gB3/gB4 genotype was detected. No statistical significance was observed between HCMV DNAemia/gB genotype and hematological alterations or severity of the disease. The high number of sickle cell disease patients with HCMV DNAemia could be due to their partial immune dysfunction (multiple transfusions, spleen dysfunction, hydroxyurea treatment). The extensive HCMV gB2 prevalence in patients with hemoglobinopathies is probably due to HCMV epidemiologic characteristics in the examined region, and can be important during the clinical management of these patients.